Company profile

Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated in
Location
Fiscal year end
Former names
Johnson & Johnson Et Al
SEC CIK
IRS number
221024240

JNJ stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

18 Feb 20
25 Feb 20
29 Dec 20

News

Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 20.75B 20.73B 20.56B 20.02B
Net income 4.01B 1.75B 5.61B 3.75B
Diluted EPS 1.5 0.66 2.08 1.39
Net profit margin 19.33% 8.46% 27.27% 18.73%
Net change in cash 1.06B 1.87B -358M -3.37B
Cash on hand 17.31B 16.25B 14.38B 14.73B
Cost of revenue 7.13B 6.87B 6.94B 6.62B
Annual (USD) Dec 19 Dec 14
Revenue 82.06B
Net income 15.12B 16.32B
Diluted EPS 5.63 5.7
Net profit margin 18.42%
Operating income 21.59B
Net change in cash 14.97B
Cash on hand 17.31B 2.34B
Cost of revenue 27.56B 22.75B

Financial data from company earnings reports

68.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2856 2658 +7.4%
Opened positions 317 94 +237.2%
Closed positions 119 123 -3.3%
Increased positions 1100 1009 +9.0%
Reduced positions 1199 1320 -9.2%
13F shares
Current Prev Q Change
Total value 2.35T 2.39T -1.7%
Total shares 1.79B 1.77B +1.5%
Total puts 12.62M 11M +14.7%
Total calls 15.48M 10.77M +43.7%
Total put/call ratio 0.8 1.0 -20.2%
Largest owners
Shares Value Change
Vanguard 228.3M $33.3B +1.0%
BLK BlackRock 192.85M $28.13B +2.2%
STT State Street 151.68M $22.13B +0.1%
Geode Capital Management 38.39M $5.59B +3.7%
State Farm Mutual Automobile Insurance 34.57M $5.04B -8.7%
BAC Bank of America 34.31M $5B +0.7%
NTRS Northern Trust 34.07M $4.97B -1.3%
BK Bank Of New York Mellon 32.85M $4.79B +3.2%
Wellington Management 27.59M $4.02B +5.8%
Massachusetts Financial Services 27.41M $4B +3.5%
Largest transactions
Shares Bought/sold Change
Capital World Investors 7.49M -9.34M -55.5%
JPM JPMorgan Chase & Co. 24.78M +5.77M +30.4%
Capital International Investors 14.72M -4.9M -25.0%
Ensign Peak Advisors 4.43M +4.43M NEW
BLK BlackRock 192.85M +4.22M +2.2%
Renaissance Technologies 2.02M -4.13M -67.2%
State Farm Mutual Automobile Insurance 34.57M -3.3M -8.7%
GS The Goldman Sachs Group, Inc. 17.2M +3.11M +22.1%
Lazard Asset Management 8.75M +3.05M +53.5%
TFC Truist Financial 3.28M +2.9M +755.9%

Financial report summary

?
Risks
  • Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
  • The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
  • Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
  • The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
  • Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
  • The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
  • The Company faces a variety of risks associated with conducting business internationally.
  • Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
  • Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
  • An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation
Management Discussion
  • For discussion on results of operations and financial condition pertaining to the fiscal years 2018 and 2017 see the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2018, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.
  • In 2019, worldwide sales increased 0.6% to $82.1 billion as compared to an increase of 6.7% in 2018. These sales changes consisted of the following:
  • The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 1.7% in 2019 and a positive impact of 0.8% in 2018.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: abatement, Abstinence, adulterated, Albritton, Alvogen, anterior, argenx, array, authentic, automated, bankruptcy, Bard, bermekimab, Biomedical, bladder, Blue, Boehringer, bosentan, broader, Brook, burden, BWI, cART, catastrophic, causally, cessation, chapter, CMS, confidence, Council, counterfeit, counterfeiting, coupled, Daubert, Density, Depressive, dermatological, destocking, detain, developmental, diagnosed, Diego, digital, duty, effort, Eleventh, Evolution, exemplary, exempt, Florham, Ford, forum, FTC, gap, globe, grew, HEC, HMO, Idaho, Ideation, implicit, indistinguishable, ineffective, Ingelheim, Intuitive, isolated, JointPoint, KINCISE, Lake, landscape, likelihood, Los, LR, magnitude, Mallincrodt, mandate, mandated, mandatory, Mapping, master, Medacta, met, misbranded, Misrepresentation, misrepresented, Monarch, MONOVISC, Mouthwash, Natco, navigation, NDMA, Neonatal, NICORETTE, noncurrent, Noramco, online, owner, Park, Patch, Pediatric, Pharm, Pharmascience, Pine, Plate, polypropylene, pre, presence, pretrial, principle, proceed, PROLENE, proof, properly, Proposition, Pty, ranitidine, Ready, reassessed, rejoined, RELIEVEA, replied, restrain, ROU, round, rounding, RSB, Sanofi, seal, seize, SF, Shandong, Sherman, Shield, shortly, smoking, Specgx, stake, standing, Subcommittee, SUBSIDIARIESCONSOLIDATED, Suicidal, Sunshine, Syndrome, SYNFIX, talcum, Tasmanian, threat, Tobacco, TRAF, transparency, true, turn, Ultrasound, unenacted, uniform, uninspected, unlicensed, Unlimited, unregulated, unresolved, unsafe, unsanitary, Ventral, Verb, Verily, Vermont, visually, vulnerability, waiving, XBiotech, Xtant, Zantac
Removed: ablation, accelerate, added, anesthetic, annualized, API, assistance, borrowed, capitalizing, charitable, Clarifying, classify, coalition, Codification, collar, concentrated, Crucell, DABAO, defer, derived, disinfection, disposed, estate, evaluate, expect, flexibility, Gamble, German, glucose, hair, Hydrogel, INCIVO, infection, invasive, knowledge, LE, living, Mesquita, microwave, minimally, NeoStrata, NeuWave, nonfinancial, Novira, overturned, pace, participating, PETITE, precise, prednisone, Procter, prospectively, recognizing, Rembrandt, reside, retroactively, retrospective, rhinocort, screen, shipped, simeprevir, slightly, soft, spend, spray, substance, supersede, telaprevir, tolling, unaffected, upheld, Vogue